Intermediate-cyclophosphamide and bortezomib for peripheral blood stem cell mobilization in multiple myeloma

Intermediate-cyclophosphamide and bortezomib for peripheral blood stem cell mobilization in multiple myeloma - IDCY-BOR PBSCH Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011503

Enrollment

Registered

2013-08-19

Start date

2013-07-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

Cyclophosphamide 2g/m2/day day2,3 div Bortezomib 1.3mg/m2/day day1,4.8.11 sc G-CSF Filgrastim 400 microgram/m2/day or Lenograstim 10microgram/kg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Performance status(ECOG)0-2 2.Adequate organ function Absolute neutrophil count; no less than 1000/mm3, platelet count; no less than 75000/mm3 AST/ALT; no less than 3 times the ULN, T-Bil; no less than 2.0mg/dl Serum creatinine; no less than 2.0mg/dl No severe cardiac failure PaO2; more than 60mmHg or SaO2; more than 90% 3.Complete informed concent

Exclusion criteria

Exclusion criteria: 1.Uncontrollable organ dysfunction(liver dysfuction, renal insufficiency, cardiac dysfunction, respiratory dysfunction, diabetes mellitus, infection) 2.Pregnant female 3.HBsAg positive, HCVAb positive, HIVAb positive 4.Coexistence of malignancy 5.Serious mental disorders 6.Those who are considered as inappropriate to register by attending physicians

Design outcomes

Primary

Measure	Time frame
Number of CD34 cells harvested Safety	—

Secondary

Measure	Time frame
CR and CR+VGPR Incidence of graft failure	—

Countries

Japan

Contacts

Public ContactAiko Sawazaki

Ishikawa Prefectural Central Hospital Department of Hematology

tristanandisolde2001@yahoo.co.jp09021285889

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026